ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "cannabinoid"

  • Abstract Number: 879 • 2019 ACR/ARP Annual Meeting

    Evaluation of Marijuana and Cannabidiol Use in the Rheumatologic Population from a Patient and Clinician Perspective: A Survey-Based Study

    Heather Goodwin 1, Ali Porter1, Melinda Edwards 1 and Bonita Libman 1, 1The University of Vermont Medical Center, Burlington, VT

    Background/Purpose: To evaluate use of marijuana (MJ) and cannabidiol (CBD) as described by rheumatology patients at an academic medical center in Vermont, and to describe beliefs and…
  • Abstract Number: 2929 • 2019 ACR/ARP Annual Meeting

    Cannabis Use Among Patients in a Large US Rheumatic Disease Registry

    Kristin Wipfler 1, Teresa Simon2, Patricia Katz 3, Frederick Wolfe 4 and Kaleb Michaud 5, 1FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, 2Bristol-Myers Squibb*, Princeton, NJ, 3University of California, San Francisco, san francisco, CA, 4FORWARD, The National Databank for Rheumatic Diseases & University of Nebraska Medical Center, Wichita, KS, 5FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS

    Background/Purpose: Legalization of cannabis use is rapidly increasing worldwide, raising the need to evaluate trends and medical implications. A systematic literature review showed inconsistent results…
  • Abstract Number: 1068 • 2018 ACR/ARHP Annual Meeting

    Characterization of the Role of Endocannabinoid System Using Jwh-133, a Selective Cannabinoid CB2 Receptor Agonist, in IL-1β-Induced Inflammation in Human Rheumatoid Arthritis Synovial Fibroblasts

    Sabrina Fechtner1, Anil K. Singh1 and Salahuddin Ahmed1,2, 1Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, 2Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA

    Background/Purpose: The endocannabinoid system (ECS) is comprised of two evolutionary conserved cannabinoid receptors 1 and 2 (CB1 and CB2) which participate in pain management through…
  • Abstract Number: 1715 • 2018 ACR/ARHP Annual Meeting

    Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects

    Robert F. Spiera1, Laura K. Hummers2, Lorinda Chung3, Tracy M. Frech4, Robyn T. Domsic5, Vivien Hsu6, Daniel E. Furst7, Jessica K. Gordon1, Maureen D. Mayes8, Robert W. Simms9, Elizabeth Lee10, Scott Constantine10 and Barbara White10, 1Hospital for Special Surgery, New York, NY, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, 4Division of Rheumatology, University of Utah, Salt Lake City, UT, 5Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 6Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, 7Pacific Arthritis Associates, Los Angeles; University of California, Los Angeles; University of Washington, Seattle; University of Florence, Italy, Los Angeles, CA, 8Rheumatology, University of Texas McGovern Medical School, Houston, TX, 9Rheumatology, Boston University School of Medicine, Boston, MA, 10Corbus Pharmaceuticals, Inc., Norwood, MA

    Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses. Lenabasum had acceptable safety and tolerability,…
  • Abstract Number: 7L • 2017 ACR/ARHP Annual Meeting

    A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis

    Victoria P. Werth1, Emily Hejazi2, Sandra M. Pena1, Jessica S. Haber3, Joyce Okawa1, Rui Feng4, Kirubel Gabre2, Josef Concha2, Caitlin Cornwall5, Nancy Dgetluck6, Scott Constantine5 and Barbara White5, 1Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Department of Dermatology, University of Pennsylvania, Philadelphia, PA, 4Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA, 5Corbus Pharmaceuticals, Inc., Norwood, MA, 6Biostatistics, Corbus Pharmaceuticals, Inc., Norwood, MA

    Background/Purpose: Effective treatment options are limited for refractory skin disease in dermatomyositis (DM). Anabasum is a non-immunosuppressive, synthetic, oral preferential CB2 agonist that triggers resolution…
  • Abstract Number: 725 • 2017 ACR/ARHP Annual Meeting

    Safety and Efficacy of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Subjects Treated in an Open-Label Extension of Trial JBT101-SSc-001

    Robert F. Spiera1, Laura K. Hummers2, Lorinda Chung3, Tracy M. Frech4, Robyn T. Domsic5, Vivien Hsu6, Daniel E. Furst7, Jessica K. Gordon1, Maureen D. Mayes8, Robert W. Simms9, Scott Constantine10 and Barbara White10, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, 3Rheumatology, Stanford University Medical Center, Palo Alto, CA, 4Division of Rheumatology, University of Utah, Salt Lake City, UT, 5Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 6Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, 7David Geffen School of Medicine at UCLA, Los Angeles, CA, 8Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 9Rheumatology, Boston University School of Medicine, Boston, MA, 10Corbus Pharmaceuticals, Inc., Norwood, MA

    Background/Purpose: Anabasum (JBT-101) is a selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses and limits fibrosis in animal models of…
  • Abstract Number: 738 • 2017 ACR/ARHP Annual Meeting

    Prospective Validation of the Systemic Sclerosis Skin Symptoms Patient-Reported Outcome (SSPRO) in a Phase 2 Trial of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

    Ada Man1, Nancy Dgetluck2 and Barbara White3, 1Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 2Biostatistics, Corbus Pharmaceuticals, Norwood, MA, 3Corbus Pharmaceuticals, Inc., Norwood, MA

    Background/Purpose: Skin thickening is the defining manifestation of dcSSc. A dcSSc patient’s assessment of their skin involvement can provide information about how that patient feels…
  • Abstract Number: 976 • 2017 ACR/ARHP Annual Meeting

    Cannabinoid Receptor 2 Agonist (JWH-015) Inhibits Interleukin-1β-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts

    Sabrina Fechtner and Salahuddin Ahmed, Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by activated synovial fibroblasts in which pro-inflammatory cytokine interleukin-1β (IL-1β) mediates inflammation. The endocannabinoid system…
  • Abstract Number: 1707 • 2017 ACR/ARHP Annual Meeting

    Effect of Anabasum (JBT-101) on Gene Expression in Skin Biopsies from Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc) and the Relationship of Baseline Molecular Subsets to Clinical Benefit in the Phase 2 Trial

    Viktor Martyanov1, Yolanda Nesbeth2, Guoshuai Cai1, Tammara A. Wood1, Jake Reder2, Scott Constantine3, Barbara White3, Robert F. Spiera4 and Michael L. Whitfield1, 1Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, 2Celdara Medical, LLC, Lebanon, NH, 3Corbus Pharmaceuticals, Inc., Norwood, MA, 4Rheumatology, Hospital for Special Surgery, New York, NY

    Background/Purpose: Anabasum (JBT-101) is a non-immunosuppressive, synthetic, CB2 agonist that resolves inflammation and fibrosis in animal models of SSc and reduces TGF-β and collagen production…
  • Abstract Number: 2884 • 2017 ACR/ARHP Annual Meeting

    A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Diffuse Cutaneous Systemic Sclerosis

    Robert F. Spiera1, Laura K. Hummers2, Lorinda Chung3, Tracy M. Frech4, Robyn T. Domsic5, Vivien Hsu6, Daniel E. Furst7, Jessica K. Gordon1, Maureen D. Mayes8, Robert W. Simms9, Scott Constantine10 and Barbara White10, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, 3Rheumatology, Stanford University Medical Center, Palo Alto, CA, 4Division of Rheumatology, University of Utah, Salt Lake City, UT, 5Rheumatology, University of Pittsburgh, Pittsburgh, PA, 6Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, 7David Geffen School of Medicine at UCLA, Los Angeles, CA, 8University of Texas McGovern Medical School, Houston, TX, 9Rheumatology, Boston University School of Medicine, Boston, MA, 10Corbus Pharmaceuticals, Inc., Norwood, MA

    Background/Purpose: Systemic sclerosis (SSc) is characterized in part by chronic activation of the innate immune system with fibrosis.  Anabasum is a non-immunosuppressive, synthetic, orally administered…
  • Abstract Number: 53 • 2016 ACR/ARHP Annual Meeting

    Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric Observational Study

    Maria Chiara Gerardi1, Alberto Batticciotto2, Rossella Talotta1, Maria Chiara Ditto1, Fabiola Atzeni2 and Piercarlo Sarzi-Puttini1, 1Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, 2Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy

    Efficacy of Cannabis flos in patients with fibromyalgia: a monocentric observational study   Background/Purpose: Fibromyalgia (FM) is a syndrome characterized by chronic widespread pain, fatigue,…
  • Abstract Number: 2789 • 2014 ACR/ARHP Annual Meeting

    Medical Marijuana Related Outcomes in Patients with Systemic Lupus Erythematosis

    Basmah Jalil1, Wilmer Sibbitt Jr.2, Romy Cabacangun3, Clifford Qualls4, Arthur Bankhurst5 and Roderick Fields6, 1Internal Medicine/Rheumatology, University of New Mexico, Albuquerque, NM, 2Internal Medicine/Rheumatology, University of New Mexico HSC, Albuquerque, NM, 3Rheumatology, UNM, Albuquerque, NM, 4Biostatistics, UNM, Albuquerque, NM, 5Rheum/ MSC 105550, University of NM Med Ctr, Albuquerque, NM, 6Internal Medicine/ Rheumatology, University of New Mexico School of Medicine, Albuquerque, NM

    Background/Purpose Medical cannabis is used extensively in the United States, usually in the form of smoked marijuana. There is growing research regarding the immunomodulatory effects…
  • Abstract Number: 1029 • 2014 ACR/ARHP Annual Meeting

    Anandamide and Related Eicosanoids Decrease the Production of Pro-Inflammatory Cytokines in Synovial Fibroblasts By a COX-2 Dependent Mechanism: Involvement of Calcium and TRP Channels

    Torsten Lowin1, Tanja Späth2, Angelika Graeber1 and Rainer Straub3, 1Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany, 2Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, Regensburg, Germany, 3Internal Medicine, University Hospital Regensburg, Regensburg, Germany

    Background/Purpose: Endocannabinoids are immunomodulatory lipid compounds that act on cannabinoid receptors type 1 and 2 but also on transient receptor potential (TRP) channels. Their action…
  • Abstract Number: 264 • 2014 ACR/ARHP Annual Meeting

    Efficacy and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials

    Tara Landry1, Mary-Ann Fitzcharles2, Peter A. Ste-Marie3 and Yoram Shir3, 1Montreal General Hospital Medical Library, Mcgill University Health Centre, Montreal, QC, Canada, 2Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, 3Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: The endocannabinoid system functions to maintain homeostasis in the human body and thereby has effects on modulation of pain and inflammation. Cannabinoid preparations are…
  • Abstract Number: 122 • 2013 ACR/ARHP Annual Meeting

    Rheumatologists Lack Confidence in Their Knowledge of Cannabinoid Molecules and Use in the Management of Rheumatic Disease Patients: Analysis of a Needs Assessment

    Mary-Ann Fitzcharles1, Peter A. Ste-Marie2, Daniel J. Clauw3, Shahin Jamal4, Jacob Karsh5, Sharon Leclercq6, Jason J. McDougall7, Yoram Shir2, Kamran Shojania8 and Zach Walsh9, 1Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, 2Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, 3Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, 4Department of Rheumatology, University of British Columbia, Vancouver, BC, Canada, 5Ottawa Hosp Riverside, Ottawa, ON, Canada, 6Division of Rheumatology, University of Calgary, Calgary, AB, Canada, 7Departments of Pharmacology and Anaesthesia, Dalhousie University, Halifax, NS, Canada, 8Rheumatology, University of British Columbia, Vancouver, BC, Canada, 9Department of Psychology, University of British Columbia, Kelowna, BC, Canada

    Background/Purpose: The pharmacologic treatment of chronic rheumatic pain is often sub-optimal, leading patients to seek alternate treatments. Although herbal cannabis (marihuana) has had medicinal use…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology